Dietary Reduction of AGEs to Prevent Cognitive Decline in Elderly Diabetics

Dietary Reduction of Advanced Glycation End Products to Prevent Cognitive Decline in Elderly Diabetics - a Randomized Pilot Trial

Basic science and observational human studies suggest that high conentrations of circulating Advanced Glycation End-products (AGEs) may promote cognitive decline in older adults. The purpose of this pilot study is to test the methodology and feasibility of a dietary intervention to lower AGEs in elderly diabetics in order to lay the foundations for a future fully powered randomized clinical trial (RCT).To this end, the present study is focused on recruitment strategies, adherence to an innovative intervention in older adults and study methods. An exploratory aim will be the effect of the intervention on cognition and cerebral blood flow in order to obtain necessary data to estimate effect-size for a future fully-powered RCT.

• Above the age 65
• T2D diagnosis
• no dementia (i.e MCI or cognitively normal )
• Not receiving cholinesterase inhibitors
• No other neurological (e.g. stroke, Parkinson's disease) or psychiatric conditions (e.g. schizophrenia, depression) that may affect cognition
• Dietary AGE levels > 13kU
• Not participating in another clinical trial
• An informant that is willing to actively support the participant throughout the study

Exclusion Criteria:

• Dementia
• Stroke
• Other major neuropsychiatric condition that might affect cognition